Over 20 years of experience in R&D

01 Drug Discovery

Chemistry Research

Biology Research

Early Pharmacokinetics

02 Pharmaceutical Research

Intermediates

Active Pharmaceutical Ingredients

Pharmaceutical preparation

Analytical Method Development and Quality Control

CMC Filings

Analytical Testing Center

03 Preclinical Research

Pharmacology & Pharmacodynamics

Drug Safety Evaluation

DMPK

Bioanalysis

IND Filings

01 One-stop Integrated Services

Liposome Drug Development Service Platform

Drug Discovery Platform

Pharmaceutical Research Platform

Preclinical Research Services

Botanical Drug Preclinical R&D Technology Platform

02 Innovative Drug Services

ADC R&D Service Platform

PROTAC R&D Service Platform

mRNA Vaccine Bioanalysis Platform

Non-clinical Research for Cellular Immunotherapies

Nucleic Acid Drug R&D Platform

Peptide Drug Conjugate (PDC) R&D Service Platform

Antibody R&D Service

03 Key Technical Services for Drug R&D

Cytokine and Biomarker Detection Platform

Metabolite Identification (MetID) Service Platform

Drug Forming Research Platform

Flow Cytometry Technology Platform

SEND Format Conversion Platform

Flow Sorting Platform

NanoString nCounter Detection Platform

Routes of Drug Administration Platform

04 Drug Efficacy Evaluation for Common Diseases

IO Pharmacodynamic Model Evaluation Platform

Pharmacodynamic Evaluation Model Platform for Inflammatory and Immune Diseases

Rodent Cerebrovascular Disease Drug Efficacy Evaluation System

05 Advanced Preparation R&D

Inhalation drug R&D platform

Ophthalmic drug R&D platform

Skin Topical Preparation R&D Platform

06 Targeted Drugs R&D Services

STAT3-targeted Drugs R&D Service

GLP-1 New Drug R&D Service

KRAS-targeted Drugs R&D Service

2024-07-22Medicilon Events

The Shanghai Overseas Returned Scholars Association invites the Dutch PhD delegation to visit Medicilon, exploring paths for innovative development together

On July 4th, the Shanghai Overseas Returned Scholars Association invited the Dutch PhD delegation to visit the Chuansha campus of Shanghai Medicilon Inc. (Medicilon) and held discussions with Medicilon's Founder and CEO, Chunlin Chen, among others.

Learn more

2024-07-22Medicilon Events

5th consecutive win! Medicilon once again made the list of "Top 20 Chinese R&D CRO Enterprises in 2024"

Medicilon stood out among hundreds of pharmaceutical enterprises and was honored with the "Top 20 Chinese R&D CRO Enterprises in 2024" award.

Medicilon 688202

RMB

As of Beijing time The data is from a third-party organization and is only for reference.

For actual information, please refer to：www.eastmoney.com

CLIENT CENTER

Intellectual Property Protection

U.S.

Address: 20 Maguire Road, Suite 103, Lexington, MA 02421(America)

Tel: +1(626)986-9880

Address: Allia Future Business Centre Kings Hedges Road Cambridge CB4 2HY, UK

Tel: 0044 7790 816 954

Email: marketing@medicilon.com

China

Address: No.585 Chuanda Road, Pudong New Area, Shanghai (Headquarters)

Postcode: 201299

Tel: +86 (21) 5859-1500 (main line)

Fax: +86 (21) 5859-6369

Shanghai Public Network Security File No. 31011502018888 | Website Map

Medicilon reached the strategic collaboration on preclinical IND application services with Welman Pharmaceutical & Mingyu New Drug

2022-07-04

Page View：

On June 23, 2022, Shanghai Medicilon Inc. (Medicilon), Welman Pharmaceutical (Welman) and Shenzhen Mingyu New Drug Research and Development Co., Ltd. (Mingyu) signed a strategic collaboration on preclinical IND application services.

According to the strategic collaboration agreement, Medicilon will assist Welman and Mingyu in advancing the R&D process of one anti-cancer drug with 4 targets, providing better preclinical solutions. At the same time, Welman and Mingyu will give priority to Medicilon as the outsourcing provider of preclinical IND application services, including but not limited to drug discovery, pharmaceutical research, preclinical research and other R&D services.

Medicilon and Welman Pharmaceutical.jpg

About Welman

Welman Pharmaceutical is a leading innovative high-tech pharmaceutical manufacturing enterprise in China. The company's core products are piperacillin sodium sulbactam sodium and cefotaxime sodium sulbactam sodium for injection. Piperacillin sodium sulbactam sodium for injection was launched in 2005, while cefotaxime sodium sulbactam sodium for injection was launched in 2009. Through extensive clinical use and market promotion in recent years, the market demand for the products has grown rapidly.

Email：marketing@medicilon.com

Welman Mingyu Preclinical-IND

Return

Relevant news